Max Kozlov Tablets of Paxlovid, which reduces risk of severe COVID-19, are inspected by a laboratory technician.Credit: Thomas Hansmann/AP/Shutterstock When clinical trial data for the antiviral drug Paxlovid emerged in late 2021, physicians hailed its astonishing efficacy — a reduction of nearly 90% in the risk of severe COVID-19. But more than a year later, COVID-19 remains...
